K. Khunti

First name
K.
Last name
Khunti
Conrad, N., Misra, S., . Y. Verbakel, J., Verbeke, G., Molenberghs, G., Taylor, P. N., et al. (2023). Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet. http://doi.org/10.1016/s0140-6736(23)00457-9
View
Ling, S., Zaccardi, F., Issa, E., Davies, M. J., Khunti, K., & Brown, K. (2023). Inequalities in cancer mortality trends in people with type 2 diabetes: 20 year population-based study in England. Diabetologia. http://doi.org/10.1007/s00125-022-05854-8
View
Meffen, A., Sayers, R. D., Gillies, C. L., Khunti, K., & Gray, L. J. (2022). Are major lower extremity amputations well recorded in primary care electronic health records?: Insights from primary care electronic health records in England. Prim Health Care Res Dev, 23, e77. http://doi.org/10.1017/s1463423622000718
View
Mizani, M. A., Dashtban, A., Pasea, L., Lai, A. G., Thygesen, J., Tomlinson, C., et al. (2022). Using national electronic health records for pandemic preparedness: validation of a parsimonious model for predicting excess deaths among those with COVID-19-a data-driven retrospective cohort study. J R Soc Med, 1410768221131897. http://doi.org/10.1177/01410768221131897
View
Karsanji, U., Evans, R. A., Quint, J. K., Khunti, K., Lawson, C. A., Petherick, E., et al. (2022). Mortality associated with metabolic syndrome in people with COPD managed in primary care. Erj Open Res, 8. http://doi.org/10.1183/23120541.00211-2022
View
Bidulka, P., Mathur, R., Lugo-Palacios, D. G., O'Neill, S., Basu, A., Silverwood, R. J., et al. (2022). Ethnic and socioeconomic disparities in initiation of second-line antidiabetic treatment in people with type 2 diabetes in England: a cross-sectional study. Diabetes Obes Metab. http://doi.org/10.1111/dom.14874
View
Idris, I., Zhang, R., Mamza, J. B., Ford, M., Morris, T., Banerjee, A., & Khunti, K. (2021). Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease. Diabetes Obes Metab, 23, 2207-2214. http://doi.org/10.1111/dom.14437
View
Wilkinson, T. J., Miksza, J., Zaccardi, F., Lawson, C., Nixon, A. C., Young, H. M. L., et al. (2022). Associations between frailty trajectories and cardiovascular, renal, and mortality outcomes in chronic kidney disease. J Cachexia Sarcopenia Muscle. http://doi.org/10.1002/jcsm.13047
View
Idris, I., Zhang, R., Mamza, J. B., Ford, M., Morris, T., Banerjee, A., & Khunti, K. (2022). Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting. Diabetes Obes Metab. http://doi.org/10.1111/dom.14799
View
Dashtban, A., Mizani, M. A., Denaxas, S., Nitsch, D., Quint, J., Corbett, R., et al. (2022). A retrospective cohort study measured predicting and validating the impact of the COVID-19 pandemic in individuals with chronic kidney disease. Kidney Int. http://doi.org/10.1016/j.kint.2022.05.015
View